Table 1. Recommendations on treatment with biologicals during the COVID-19 pandemic in patients with asthma, atopic dermatitis, urticaria, or CRSwNP.

Recommendations for biological treatment in non-infected patients during the COVID-19 pandemic or in patients who have recovered from COVID-19 infection	Recommendations for biological treatment in patients with diagnosed or suspected SARS-CoV-2 infection
Termination of biological treatment is not generally necessary; and biologicals should be continued as scheduled, particularly in severe cases, based on an individual risk-benefit analysis.	In mild-to-moderate COVID-19 courses, or when SARS-CoV-2 infection is suspected, biologicals can be continued in the indications discussed here if a patient-based risk-benefit analysis supports the decision and the patient consents after having been informed about the limited availability of data.
Prolongation of the injection interval can be considered (as indicated in the summary of product characteristics) to limit the necessary physician-patient contacts to a minimum.	In severe COVID-19 courses, prolongation of the injection interval (as indicated in the summary of product characteristics) or treatment interruption should be considered in the indications discussed here. The risk of the possible requirement of systemic glucocorticosteroids must be considered.
Biological treatment can be continued during the current COVID-19 pandemic in asymptomatic patients with negative PCR tests, in patients without known exposure or contact with SARS-CoV-2-positive people, and in patients who have completed an adequate quarantine period.	In a quarantine situation, telemedical support might be feasible, in particular with the aim of continuing the basic therapy with topical steroids, inhaled bronchodilators, antihistamines, etc. in accordance with the relevant guideline recommendations or with the aim to expand those therapies according to the patient’s needs.
Biological therapy in patients without evidence of SARS-CoV-2 infection can be started for approved indications
During the current COVID-19 pandemic, self-administration of biologicals should generally be preferred; this is made easier if user-friendly pen systems for self-application are available. Adequate patient training is required.
Practices and allergy centers must be prepared for the current COVID-19 pandemic by following the recommendations of the WHO and of national and regional authorities.
These recommendations should be continuously updated and adapted to new scientific findings and recommendations made by authorities.

CRSwNP = chronic rhinosinusitis with nasal polyps.